ArticleCNS neuroscience & therapeutics2026
Transcutaneous Auricular Vagus Nerve Stimulation Alleviates Oxidative Stress and Improves Neurological Outcomes After Traumatic Brain Injury in Mice.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transcutaneous Auricular Vagus Nerve Stimulation Alleviates Oxidative Stress and Improves Neurological Outcomes After Traumatic Brain Injury in Mice.CNS neuroscience & therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveTraumatic brain injury (TBI) can trigger secondary oxidative stress and exacerbate neurological dysfunction. This study investigated whether transcutaneous auricular vagus nerve stimulation (taVNS) attenuates oxidative stress and improves neurological recovery after TBI in mice.
methodsThe TBI model was established using a controlled cortical impact (CCI) model. Seventy C57BL/6 mice were divided into the sham group, TBI group, taVNS group, MDHB (pathway agonist, administered alone) group, and ML385 (pathway inhibitor, administered 30 min before each taVNS session) group. Outcomes were assessed by Western blotting, ELISA, immunofluorescence, T2-weighted MRI-based volumetric quantification of edema, and behavioral tests.
resultsTBI markedly increased oxidative stress and neurological impairment, as reflected by reduced serum glutathione (GSH) and superoxide dismutase (SOD) levels, increased lesion and edema burden on MRI, and worsened behavioral performance. TaVNS significantly alleviated these changes, increasing GSH and SOD levels, reducing edema burden, and improving mNSS and open-field performance. In addition, taVNS was associated with increased expression of antioxidant-related proteins, including Nrf-2 and HO-1, whereas pharmacological inhibition with ML385 attenuated these beneficial effects.
conclusionThese findings suggest that taVNS may alleviate oxidative stress and improve neurological outcomes after TBI in mice, with possible involvement of the Nrf-2/HO-1 pathway.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.